156 related articles for article (PubMed ID: 28123577)
1. Per2 participates in AKT-mediated drug resistance in A549/DDP lung adenocarcinoma cells.
Chen B; Tan Y; Liang Y; Li Y; Chen L; Wu S; Xu W; Wang Y; Zhao W; Wu J
Oncol Lett; 2017 Jan; 13(1):423-428. PubMed ID: 28123577
[TBL] [Abstract][Full Text] [Related]
2. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
3. Circadian Clock Protein PERIOD2 Suppresses the PI3K/Akt Pathway and Promotes Cisplatin Sensitivity in Ovarian Cancer.
Wang Z; Li F; Wei M; Zhang S; Wang T
Cancer Manag Res; 2020; 12():11897-11908. PubMed ID: 33244267
[TBL] [Abstract][Full Text] [Related]
4. Depleted aldehyde dehydrogenase 1A1 (ALDH1A1) reverses cisplatin resistance of human lung adenocarcinoma cell A549/DDP.
Wei Y; Wu S; Xu W; Liang Y; Li Y; Zhao W; Wu J
Thorac Cancer; 2017 Jan; 8(1):26-32. PubMed ID: 27813328
[TBL] [Abstract][Full Text] [Related]
5. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
Shi H; Pu J; Zhou XL; Ning YY; Bai C
Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
[TBL] [Abstract][Full Text] [Related]
6. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
8. CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway.
Zhang R; Sun S; Ji F; Liu C; Lin H; Xie L; Yang H; Tang W; Zhou Y; Xu J; Li P
Cell Physiol Biochem; 2017; 43(2):465-480. PubMed ID: 28934754
[TBL] [Abstract][Full Text] [Related]
9. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
[TBL] [Abstract][Full Text] [Related]
10. Anti-apoptotic brain and reproductive organ-expressed proteins enhance cisplatin resistance in lung cancer cells via the protein kinase B signaling pathway.
Li Y; Qi K; Zu L; Wang M; Wang Y; Zhou Q
Thorac Cancer; 2016 Mar; 7(2):190-8. PubMed ID: 27042221
[TBL] [Abstract][Full Text] [Related]
11. Metformin reverses the resistance mechanism of lung adenocarcinoma cells that knocks down the Nrf2 gene.
Zhang J; Jiao K; Liu J; Xia Y
Oncol Lett; 2018 Nov; 16(5):6071-6080. PubMed ID: 30333878
[TBL] [Abstract][Full Text] [Related]
12. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
Chen J; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):285-92. PubMed ID: 27116987
[TBL] [Abstract][Full Text] [Related]
13. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2.
He R; Liu H
Gene; 2020 Jul; 747():144553. PubMed ID: 32165307
[TBL] [Abstract][Full Text] [Related]
14. Honokiol combined with curcumin sensitizes multidrug-resistant human lung adenocarcinoma A549/DDP cells to cisplatin.
Qi M; Chen X; Bian L; Zhang H; Ma J
Exp Ther Med; 2021 Nov; 22(5):1301. PubMed ID: 34630656
[TBL] [Abstract][Full Text] [Related]
15. Down-Regulating the Expression of miRNA-21 Inhibits the Glucose Metabolism of A549/DDP Cells and Promotes Cell Death Through the PI3K/AKT/mTOR/HIF-1α Pathway.
Sun Y; Liu W; Zhao Q; Zhang R; Wang J; Pan P; Shang H; Liu C; Wang C
Front Oncol; 2021; 11():653596. PubMed ID: 34046349
[TBL] [Abstract][Full Text] [Related]
16. Polyphyllin I and VII potentiate the chemosensitivity of A549/DDP cells to cisplatin by enhancing apoptosis, reversing EMT and suppressing the CIP2A/AKT/mTOR signaling axis.
Feng F; Cheng P; Wang C; Wang Y; Wang W
Oncol Lett; 2019 Nov; 18(5):5428-5436. PubMed ID: 31612051
[TBL] [Abstract][Full Text] [Related]
17. Baicalin attenuates DDP (cisplatin) resistance in lung cancer by downregulating MARK2 and p-Akt.
Xu Z; Mei J; Tan Y
Int J Oncol; 2017 Jan; 50(1):93-100. PubMed ID: 27878245
[TBL] [Abstract][Full Text] [Related]
18. AFAP1-AS1 induces cisplatin resistance in non-small cell lung cancer through PI3K/AKT pathway.
Liu Y; Hu Q; Wang X
Oncol Lett; 2020 Jan; 19(1):1024-1030. PubMed ID: 31897216
[TBL] [Abstract][Full Text] [Related]
19. C-Myc participates in β-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma cells.
Xie C; Pan Y; Hao F; Gao Y; Liu Z; Zhang X; Xie L; Jiang G; Li Q; Wang E
APMIS; 2014 Dec; 122(12):1251-8. PubMed ID: 25131138
[TBL] [Abstract][Full Text] [Related]
20. Tripchlorolide induces autophagy in lung cancer cells by inhibiting the PI3K/AKT/mTOR pathway and improves cisplatin sensitivity in A549/DDP cells.
Chen LM; Song TJ; Xiao JH; Huang ZH; Li Y; Lin TY
Oncotarget; 2017 Sep; 8(38):63911-63922. PubMed ID: 28969040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
